Cubist Systematic Strategies LLC Buys 53,313 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Cubist Systematic Strategies LLC raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 282.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 72,207 shares of the company's stock after buying an additional 53,313 shares during the period. Cubist Systematic Strategies LLC owned about 0.11% of Replimune Group worth $650,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock valued at $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Replimune Group during the 2nd quarter valued at about $57,000. Diversified Trust Co purchased a new position in shares of Replimune Group during the first quarter valued at about $94,000. China Universal Asset Management Co. Ltd. raised its stake in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company's stock worth $96,000 after buying an additional 4,975 shares in the last quarter. Finally, Arizona State Retirement System purchased a new stake in Replimune Group in the second quarter worth about $108,000. Institutional investors own 92.53% of the company's stock.

Replimune Group Stock Up 3.2 %

Replimune Group stock traded up $0.36 during mid-day trading on Friday, reaching $11.48. The stock had a trading volume of 461,594 shares, compared to its average volume of 1,107,604. The company has a market capitalization of $705.04 million, a price-to-earnings ratio of -3.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $15.48. The company has a 50-day moving average price of $10.62 and a two-hundred day moving average price of $8.74.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.10. On average, analysts expect that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

Insider Transactions at Replimune Group

In related news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the sale, the chief financial officer now directly owns 101,057 shares of the company's stock, valued at $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 20.60% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Roth Capital raised Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Replimune Group in a research report on Monday, September 16th. JPMorgan Chase & Co. lifted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research report on Tuesday, September 24th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $16.80.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.